| 9.31 -0.115 (-1.22%) | 01-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.61 | 1-year : | 12.96 |
| Resists | First : | 9.94 | Second : | 11.1 |
| Pivot price | 9.61  |
|||
| Supports | First : | 8.07 | Second : | 6.72 |
| MAs | MA(5) : | 9.66 |
MA(20) : | 9.44  |
| MA(100) : | 10.63 |
MA(250) : | 10.05 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 34.5 |
D(3) : | 43.6 |
| RSI | RSI(14): 48.7 |
|||
| 52-week | High : | 17.57 | Low : | 5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ DNA ] has closed above bottom band by 30.7%. Bollinger Bands are 56.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 9.38 - 9.47 | 9.47 - 9.53 |
| Low: | 8.91 - 9.02 | 9.02 - 9.09 |
| Close: | 9.17 - 9.37 | 9.37 - 9.49 |
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Thu, 29 Jan 2026
Ginkgo Bioworks Holdings, Inc. (DNA) Declines More Than Market: Some Information for Investors - sharewise.com
Fri, 23 Jan 2026
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Wed, 14 Jan 2026
Ginkgo Bioworks Holdings, Inc. (DNA) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Sun, 11 Jan 2026
Why The Narrative Around Ginkgo Bioworks Holdings (DNA) Is Shifting After New Fair Value Reset - Yahoo Finance
Thu, 08 Jan 2026
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Dips While Market Gains: Key Facts - Nasdaq
Wed, 31 Dec 2025
Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key Facts - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 49 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 3.4 (%) |
| Held by Institutions | 71.5 (%) |
| Shares Short | 6,670 (K) |
| Shares Short P.Month | 6,630 (K) |
| EPS | -6.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.85 |
| Profit Margin | -188 % |
| Operating Margin | -227.3 % |
| Return on Assets (ttm) | -15.6 % |
| Return on Equity (ttm) | -50.1 % |
| Qtrly Rev. Growth | -56.5 % |
| Gross Profit (p.s.) | 2.7 |
| Sales Per Share | 3.72 |
| EBITDA (p.s.) | -5.61 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -166 (M) |
| Levered Free Cash Flow | -81 (M) |
| PE Ratio | -1.51 |
| PEG Ratio | 0 |
| Price to Book value | 0.94 |
| Price to Sales | 2.5 |
| Price to Cash Flow | -2.73 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|